X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-12 | MDGL | Madrigal Pharmaceuticals, Inc. | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale+OE | $285.00 | -2,000 | 5,500 | -27% | -$570,000 | |||||
| D | 2024-06-12 | RNA | Avidity Biosciences, Inc. | Maclean Michael F | CFO | S - Sale+OE | $35.72 | -104,245 | 44,093 | -70% | -$3,723,141 | |||||
| DM | 2024-06-12 | RNA | Avidity Biosciences, Inc. | Levin Arthur A | Dir | S - Sale+OE | $38.07 | -100,000 | 168,702 | -37% | -$3,807,410 | |||||
| DM | 2024-06-12 | RNA | Avidity Biosciences, Inc. | Boyce Sarah | Pres, CEO | S - Sale+OE | $38.63 | -300,000 | 112,117 | -73% | -$11,588,306 | |||||
| M | 2024-06-12 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $12.70 | -72,797 | 976,271 | -7% | -$924,203 | |||||
2024-06-14 | NKTR | Nektar Therapeutics | Chess Robert | Dir | S - Sale | $1.20 | -19,500 | 261,573 | -7% | -$23,400 | ||||||
| D | 2024-06-14 | AVTE | Aerovate Therapeutics, Inc. | Eldridge George A | SEE REMARKS | S - Sale+OE | $25.03 | -15,000 | 5,022 | -75% | -$375,450 | |||||
| D | 2024-06-14 | AVTE | Aerovate Therapeutics, Inc. | Verwijs Marinus | CHIEF TECHNICAL OFFICER | S - Sale+OE | $25.00 | -10,600 | 0 | -100% | -$265,000 | |||||
| D | 2024-06-13 | AVTE | Aerovate Therapeutics, Inc. | Gillies Hunter | CHIEF MEDICAL OFFICER | S - Sale+OE | $24.50 | -6,000 | 5,602 | -52% | -$147,000 | |||||
2024-06-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $63.80 | -250 | 59,231 | 0% | -$15,950 | ||||||
| M | 2024-06-12 | TLPH | Talphera, Inc. | Angotti Vincent J. | CEO | P - Purchase | $0.99 | +10,000 | 180,806 | +6% | +$9,856 | |||||
2024-06-14 | KPRX | Kiora Pharmaceuticals Inc | Tosca Melissa | EVP Finance | P - Purchase | $5.25 | +100 | 3,979 | +3% | +$525 | ||||||
2024-06-13 | TRDA | Entrada Therapeutics, Inc. | Doshi Dipal | CEO | S - Sale | $16.17 | -1,000 | 336,375 | 0% | -$16,174 | ||||||
| D | 2024-06-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $285.48 | -3,600 | 647,195 | -1% | -$1,027,716 | |||||
| D | 2024-06-13 | UTHR | United Therapeutics Corp | Causey Christopher | Dir | S - Sale+OE | $281.53 | -2,000 | 4,185 | -32% | -$563,055 | |||||
2024-06-12 | ARCT | Arcturus Therapeutics Holdings Inc. | Sassine Andy | CFO | S - Sale | $32.03 | -50,000 | 220,526 | -18% | -$1,601,500 | ||||||
2024-06-14 | KPRX | Kiora Pharmaceuticals Inc | Daniels Eric Joseph | Chief Development Officer | P - Purchase | $5.29 | +1,431 | 11,222 | +15% | +$7,570 | ||||||
2024-06-14 | RZLT | Rezolute, Inc. | Roberts Brian Kenneth | Chief Medical Officer | P - Purchase | $3.91 | +7,600 | 68,728 | +12% | +$29,743 | ||||||
2024-06-14 | RZLT | Rezolute, Inc. | Evans Daron | CFO | P - Purchase | $4.04 | +40,000 | 203,351 | +24% | +$161,568 | ||||||
2024-06-13 | ANIX | Anixa Biosciences Inc | Titterton Lewis H Jr | Dir | P - Purchase | $2.70 | +405 | 856,612 | 0% | +$1,094 | ||||||
| D | 2024-06-12 | DYN | Dyne Therapeutics, Inc. | High Susanna Gatti | COO | S - Sale+OE | $33.36 | -40,000 | 148,792 | -21% | -$1,334,201 | |||||
2024-06-11 | NEXI | Neximmune, Inc. | Jones Kristi | Pres, CEO | P - Purchase | $0.01 | +1 | 1 | New | +$0 | ||||||
| D | 2024-06-13 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $17.02 | -1,864 | 19,838 | -9% | -$31,721 | |||||
2024-06-12 | ZOM | Zomedica Corp. | Klass Russell Kevin | VP of Sales | P - Purchase | $0.16 | +299,993 | 2,000,050 | +18% | +$46,529 | ||||||
2024-06-12 | PCRX | Pacira Biosciences, Inc. | Riker Lauren | SVP, Finance | S - Sale | $28.72 | -3,970 | 38,075 | -9% | -$114,018 | ||||||
2024-06-11 | PCRX | Pacira Biosciences, Inc. | Slonin Jonathan | Chief Medical Officer | S - Sale | $28.57 | -5,012 | 98,869 | -5% | -$143,193 | ||||||
2024-06-11 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | COO | S - Sale | $22.64 | -2,516 | 310,790 | -1% | -$56,965 | ||||||
2024-06-13 | PCRX | Pacira Biosciences, Inc. | Gaugler Daryl | COO | S - Sale | $28.38 | -1,000 | 116,040 | -1% | -$28,380 | ||||||
| D | 2024-06-13 | PCRX | Pacira Biosciences, Inc. | Hastings Paul J | Dir | S - Sale+OE | $28.38 | -880 | 12,724 | -6% | -$24,974 | |||||
2024-06-13 | PCRX | Pacira Biosciences, Inc. | Williams Kristen | Chief Administrative Officer | S - Sale | $28.38 | -7,452 | 102,912 | -7% | -$211,488 | ||||||
2024-06-11 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale | $22.64 | -2,825 | 74,867 | -4% | -$63,961 | ||||||
2024-06-11 | AKRO | Akero Therapeutics, Inc. | White William Richard | CFO | S - Sale | $22.64 | -2,831 | 46,799 | -6% | -$64,094 | ||||||
2024-06-11 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale | $22.64 | -2,380 | 180,178 | -1% | -$53,886 | ||||||
2024-06-11 | AKRO | Akero Therapeutics, Inc. | Lamy Patrick | SVP, Commercial Strategy | S - Sale | $22.64 | -569 | 18,562 | -3% | -$12,883 | ||||||
| M | 2024-06-11 | ACRS | Aclaris Therapeutics, Inc. | Leonard Braden Michael | 10% | P - Purchase | $1.11 | +1,611,200 | 11,007,134 | +17% | +$1,781,897 | |||||
2024-06-11 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Pres, CEO | S - Sale | $22.64 | -7,894 | 581,553 | -1% | -$178,728 | ||||||
2024-06-11 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | CFO, Secretary | S - Sale | $12.94 | -96,815 | 255,462 | -27% | -$1,252,718 | ||||||
| DM | 2024-06-11 | PEPG | Pepgen Inc. | Mellion Michelle L | Chief Medical Officer | S - Sale+OE | $18.06 | -1,586 | 0 | -100% | -$28,637 | |||||
2024-06-11 | NUVB | Nuvation Bio Inc. | Blickenstaff Kim D | Dir | P - Purchase | $2.90 | +172,189 | 172,189 | New | +$500,089 | ||||||
| M | 2024-06-11 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.14 | -100,000 | 12,565,600 | -1% | -$913,917 | |||||
2024-06-12 | FGEN | Fibrogen Inc | Adib Deyaa | Chief Medical Officer | P - Purchase | $1.17 | +22,123 | 82,123 | +37% | +$25,884 | ||||||
| DM | 2024-06-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $278.45 | -7,200 | 647,195 | -1% | -$2,004,851 | |||||
| M | 2024-06-11 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.14 | -100,000 | 12,565,600 | -1% | -$913,917 | |||||
2024-06-12 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $478.00 | -2,280 | 32,379 | -7% | -$1,089,840 | ||||||
2024-06-12 | VRTX | Vertex Pharmaceuticals Inc / Ma | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Offi | S - Sale | $478.00 | -7,288 | 15,972 | -31% | -$3,483,664 | ||||||
| DM | 2024-06-11 | REGN | Regeneron Pharmaceuticals, Inc. | Schleifer Leonard S | Bd. Co-Chair, Pres, CEO | S - Sale+OE | $1,015.75 | -25,213 | 670,346 | -4% | -$25,610,229 | |||||
2024-06-13 | KPRX | Kiora Pharmaceuticals Inc | Parsons Erin | Dir | P - Purchase | $4.88 | +5,260 | 5,260 | New | +$25,669 | ||||||
2024-06-13 | KPRX | Kiora Pharmaceuticals Inc | Strem Brian M. | Pres, CEO | P - Purchase | $5.00 | +3,000 | 14,531 | +26% | +$14,997 | ||||||
2024-06-12 | RARE | Ultragenyx Pharmaceutical Inc. | Parschauer Karah Herdman | EVP, GC | S - Sale | $45.00 | -9,806 | 57,981 | -14% | -$441,270 | ||||||
| D | 2024-06-12 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $17.01 | -1,900 | 19,838 | -9% | -$32,319 | |||||
| M | 2024-06-10 | KRON | Kronos Bio, Inc. | Bischofberger Norbert W | Pres, CEO | P - Purchase | $1.04 | +3,005,122 | 11,241,620 | +36% | +$3,119,081 | |||||
| M | 2024-06-10 | ALRN | Aileron Therapeutics, Inc. | University of Texas/Texas Am Investment Management Co | 10% | S - Sale | $3.27 | -24,671 | 1,753,156 | -1% | -$80,710 | |||||
2024-06-11 | ASRT | Assertio Holdings, Inc. | Vacirca Jeff L | Dir | P - Purchase | $1.11 | +10,000 | 151,159 | +7% | +$11,100 | ||||||
| DM | 2024-06-10 | MRUS | Merus N.V. | Shuman Harry | VP Controller, PAO | S - Sale+OE | $57.28 | -8,300 | 7,002 | -54% | -$475,456 | |||||
2024-06-11 | BMEA | Biomea Fusion, Inc. | Valle Franco | CFO | P - Purchase | $4.43 | +12,509 | 42,500 | +42% | +$55,361 | ||||||
2024-06-10 | DAWN | Day One Biopharmaceuticals, Inc. | Blackman Samuel C. | HEAD OF R, D | S - Sale | $12.62 | -30,000 | 2,141,081 | -1% | -$378,588 | ||||||
| D | 2024-06-10 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $60.00 | -21,195 | 106,134 | -17% | -$1,271,700 | |||||
| M | 2024-06-10 | ZOM | Zomedica Corp. | Klass Russell Kevin | VP of Sales | P - Purchase | $0.15 | +700,007 | 1,700,057 | +70% | +$105,041 | |||||
| D | 2024-06-10 | GERN | Geron Corp | Feller Faye | EVP, Chief Medical Officer | S - Sale+OE | $4.63 | -287,900 | 0 | -100% | -$1,334,129 | |||||
| D | 2024-06-10 | GERN | Geron Corp | Kapur Anil | EVP, Corp Strategy, CCO | S - Sale+OE | $4.65 | -421,875 | 0 | -100% | -$1,959,609 | |||||
2024-06-10 | IRWD | Ironwood Pharmaceuticals Inc | McHugh Julie | Dir | S - Sale | $6.29 | -22,766 | 139,528 | -14% | -$143,198 | ||||||
| M | 2024-06-10 | ANIX | Anixa Biosciences Inc | Titterton Lewis H Jr | Dir | P - Purchase | $2.66 | +7,432 | 856,207 | +1% | +$19,749 | |||||
2024-06-07 | JAZZ | Jazz Pharmaceuticals Plc | Carr Patricia | SVP, Chief Accounting Officer | S - Sale | $108.83 | -163 | 6,596 | -2% | -$17,738 | ||||||
2024-06-10 | YMAB | Y-Mabs Therapeutics, Inc. | Ber Gerard | Dir | S - Sale | $12.00 | -722 | 1,608 | -31% | -$8,664 | ||||||
| M | 2024-06-10 | YMAB | Y-Mabs Therapeutics, Inc. | Gad Thomas | CHIEF BUSINESS OFFICER | S - Sale | $12.02 | -70,000 | 381,381 | -16% | -$841,050 | |||||
2024-06-11 | DYN | Dyne Therapeutics, Inc. | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $31.34 | -2,136 | 147,511 | -1% | -$66,942 | ||||||
2024-06-11 | DYN | Dyne Therapeutics, Inc. | Farwell Wildon | Chief Medical Officer | S - Sale | $31.27 | -2,636 | 145,543 | -2% | -$82,428 | ||||||
| DM | 2024-06-10 | DYN | Dyne Therapeutics, Inc. | High Susanna Gatti | COO | S - Sale+OE | $30.30 | -85,270 | 148,792 | -36% | -$2,583,782 | |||||
2024-06-11 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Officer | S - Sale | $31.34 | -1,823 | 134,811 | -1% | -$57,133 | ||||||
| M | 2024-06-10 | DYN | Dyne Therapeutics, Inc. | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale | $30.74 | -2,921 | 113,774 | -3% | -$89,779 | |||||
2024-06-10 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale | $41.40 | -3,000 | 78,409 | -4% | -$124,200 | ||||||
| D | 2024-06-10 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $14.79 | -975 | 34,564 | -3% | -$14,420 | |||||
2024-06-07 | CPRX | Catalyst Pharmaceuticals, Inc. | Del Carmen Jeffrey | Chief Commercial Officer | S - Sale | $16.07 | -7,541 | 18,427 | -29% | -$121,184 | ||||||
2024-06-07 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | Pres, CEO | P - Purchase | $0.74 | +1,000 | 20,990 | +5% | +$740 | ||||||
2024-06-10 | CRNX | Crinetics Pharmaceuticals, Inc. | Betz Stephen F. | Chief Scientific Officer | S - Sale | $43.86 | -3,000 | 83,643 | -3% | -$131,580 | ||||||
| D | 2024-06-07 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Dir | S - Sale+OE | $35.00 | -8,000 | 12,000 | -40% | -$280,000 | |||||
2024-06-07 | PTGX | Protagonist Therapeutics, Inc | Patel Dinesh V Ph D | Pres, CEO | S - Sale | $35.19 | -35,000 | 515,415 | -6% | -$1,231,650 | ||||||
| DM | 2024-06-07 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $275.54 | -7,200 | 647,195 | -1% | -$1,983,862 | |||||
| D | 2024-06-11 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $53.04 | -7,788 | 135,004 | -5% | -$413,106 | |||||
2024-06-10 | ZOM | Zomedica Corp. | Donato Peter | CFO | P - Purchase | $0.15 | +25,000 | 25,000 | New | +$3,798 | ||||||
2024-06-10 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $860.78 | -75,510 | 97,793,810 | 0% | -$64,997,274 | ||||||
| D | 2024-06-10 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale+OE | $13.08 | -5,153 | 144,284 | -3% | -$67,401 | |||||
2024-06-10 | RARE | Ultragenyx Pharmaceutical Inc. | Sanders Corazon (Corsee) D. | Dir | S - Sale | $41.10 | -1,737 | 7,248 | -19% | -$71,391 | ||||||
| D | 2024-06-10 | RAPP | Rapport Therapeutics, Inc. | Healy James | Dir | P - Purchase | $17.00 | +558,824 | 1,951,562 | +40% | +$9,500,008 | |||||
| M | 2024-06-07 | TYRA | Tyra Biosciences, Inc. | Bensen Daniel | COO | S - Sale | $20.00 | -3,702 | 427,981 | -1% | -$74,045 | |||||
| D | 2024-06-06 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $20.06 | -1,133 | 394,027 | 0% | -$22,722 | |||||
| D | 2024-06-07 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $11.53 | -7,465 | 224,547 | -3% | -$86,068 | |||||
2024-06-06 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | Pres, CEO | P - Purchase | $0.75 | +1,000 | 19,990 | +5% | +$750 | ||||||
| M | 2024-06-06 | IRWD | Ironwood Pharmaceuticals Inc | Moukheibir Catherine | Dir | S - Sale | $6.47 | -80,000 | 48,633 | -62% | -$517,694 | |||||
2024-06-06 | APLT | Applied Therapeutics, Inc. | Shendelman Shoshana | Pres, CEO, 10% | S - Sale | $4.32 | -61,795 | 8,086,510 | -1% | -$266,954 | ||||||
2024-06-06 | APLT | Applied Therapeutics, Inc. | Perfetti Riccardo | Chief Medical Officer | S - Sale | $4.32 | -22,003 | 1,009,534 | -2% | -$95,053 | ||||||
| D | 2024-06-07 | THRD | Third Harmonic Bio, Inc. | Dittman Jennifer | Chief Development Oper Officer | S - Sale+OE | $14.17 | -494 | 0 | -100% | -$7,000 | |||||
2024-06-06 | APLT | Applied Therapeutics, Inc. | Funtleyder Leslie D. | CFO | S - Sale | $4.32 | -16,980 | 291,441 | -6% | -$73,354 | ||||||
2024-06-10 | CYTK | Cytokinetics Inc | Bhanji Muna | Dir | S - Sale | $52.07 | -2,000 | 17,631 | -10% | -$104,140 | ||||||
2024-06-07 | QNRX | Quoin Pharmaceuticals, Ltd. | Langer Dennis | Dir | S - Sale | $0.73 | -297 | 53 | -85% | -$217 | ||||||
2024-06-06 | REGN | Regeneron Pharmaceuticals, Inc. | Schleifer Leonard S | Bd. Co-Chair, Pres, CEO | S - Sale | $1,015.02 | -787 | 694,559 | 0% | -$798,821 | ||||||
2024-06-07 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $852.30 | -139,490 | 97,869,320 | 0% | -$118,886,587 | ||||||
| A | 2024-03-21 | RCKT | Rocket Pharmaceuticals, Inc. | Makker Gotham | Dir | S - Sale | $28.43 | -274,000 | 987,412 | -22% | -$7,790,943 | |||||
2024-06-07 | ANIX | Anixa Biosciences Inc | Titterton Lewis H Jr | Dir | P - Purchase | $2.52 | +10,738 | 848,775 | +1% | +$27,060 | ||||||
2024-06-07 | IMMX | Immix Biopharma, Inc. | Rachman Ilya M | CEO, COB | P - Purchase | $2.13 | +2,600 | 1,136,259 | 0% | +$5,538 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |